| Gene symbol | MAGEA4 | Synonyms | CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A4 | ||||
| GTO ID | GTC2595 |
| Trial ID | NCT04752358 |
| Disease | Esophagogastric Junction Cancer | Esophageal Cancer |
| Altered gene | MAGE-A4 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | ADP-A2M4CD8 |
| HLA | HLA-A*02 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers |
| Year | 2021 |
| Country | United States |
| Company sponsor | Adaptimmune |
| Other ID(s) | ADP-0055-002 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||